Rho Kinase: Inhibitors as Novel Anti-Cancer Agents

  • ROCK1, or Rho kinase, is a protein kinase activated by Rho that plays a signaling role in cell morphology, transformation, motility, focal adhesion, and cytokinesis.

  • Inhibition of this pathway may prevent tumor cell motility and metastasis.

  • Novel small-molecule inhibitors of ROCK1 have been synthesized and assayed for activity in vitro, and are candidates as anti-cancer drugs.

FEATURES AND BENEFITS

  • Novel compounds have been synthesized that exhibit strong inhibition of ROCK1, offering potentially high potency.

  • The synthetic routes are short and have high yields.

  • The inhibitors have improved selectivity for ROCK1 over other protein kinases, offering potential as superior targeted agents.

STAGE OF DEVELOPMENT

Lead optimization.

PATENTS

Patent application filed

Contact

Haskell Adler PhD MBA
Senior Licensing Manager
Haskell.Adler@Moffitt.org
(813) 745-6596

06B134